https://assets.capyfin.com/instruments/678fdc13234e27009c5d5c63.png avatar
Halozyme
🇺🇸 NASDAQ:HALO
View Company
OverviewEarningsDividends
•
Dec 31, 2019

Halozyme Q4 2019 Earnings Report

Reported financial results for the fourth quarter and full year ended December 31, 2019.

Key Takeaways

Halozyme's fourth-quarter revenue was $53.7 million, compared to $60.2 million for the fourth quarter of 2018. The net loss for the fourth quarter was $34.4 million, or $0.24 per share, compared to a net loss in the fourth quarter of 2018 of $2.1 million, or $0.01 per share. The company completed $200 million worth of share repurchases under the Board of Directors authorized capital return program.

Halozyme is reiterating its 2020 financial guidance ranges as first announced on January 14, 2020.

Janssen selected for development with ENHANZE® the targets EGFR and cMET on an exclusive basis as part of the bispecific antibody (JNJ-61186372), which is being studied in solid tumors.

Company plans to repurchase up to an additional $150M worth of shares in 2020.

Strategic actions to reposition the Company with a focus on its ENHANZE® drug delivery technology and immediately implemented a restructuring following the announcement of results of the HALO-301 clinical study.

Total Revenue
$53.7M
Previous year: $60.2M
-10.9%
EPS
-$0.24
Previous year: -$0.01
+2300.0%
Cash and marketable securities
$421M
Gross Profit
$37M
Previous year: $5.06M
+631.4%
Cash and Equivalents
$120M
Previous year: $57.9M
+107.4%
Free Cash Flow
-$27.3M
Previous year: $7.39M
-469.0%
Total Assets
$566M
Previous year: $440M
+28.5%

Halozyme

Halozyme

Halozyme Revenue by Segment

Forward Guidance

Halozyme is reiterating its 2020 financial guidance ranges as first announced on January 14, 2020. For 2020 Halozyme expects revenues of $230 million to $245 million, representing growth of 17% to 25%; Earnings per share on a GAAP basis of $0.60 to $0.75 with the first quarter of sustainable profitability beginning in Q2 2020.

Positive Outlook

  • Revenues of $230 million to $245 million, representing growth of 17% to 25%
  • Earnings per share on a GAAP basis of $0.60 to $0.75
  • First quarter of sustainable profitability beginning in Q2 2020
  • Multiple events that will grow the value of our ENHANZE® technology in 2020.
  • Transition to profitability and plans for continued return of capital

Challenges Ahead

  • Unexpected levels of revenues, expenditures and costs
  • Unexpected delays in the execution of the Company's share repurchase program
  • Unexpected results or delays in the growth of the Company’s ENHANZE® business
  • Unexpected adverse events
  • Competitive conditions

Revenue & Expenses

Visualization of income flow from segment revenue to net income

Company Overview

Full financial data and analysis

View Halozyme